Taniraleucel

坦尼瑞仑赛

Report date: 2024/11/22 20:00:28

Base Information

Drug NameTaniraleucel
Drug Alias NameCord-blood-derived-natural-killer-cells-CelgenePNK-007CYNK-001CAR19-CYNK
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionImmunostimulantsNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)PainImmunoproliferative Disorders +[33] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCelgene Corp
China Registration ClassN/A

Develop Information

Active CompaniesSorrento Therapeutics IncCelularity Inc
Inactive CompaniesN/A
Active IndicationsPainImmunoproliferative DisordersLymphoproliferative Disorders +[12] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Immune System DiseasesCardiovascular Diseases +[21] 

Other Information

ATC CodeN/A
Related LinksN/A